58914-34-4

Usage

Uses

Used in Pharmaceutical Industry:
2-Formyl-5-(trifluoromethyl)phenol, 4-Formyl-3-hydroxybenzotrifluoride, and 4-(Trifluoromethyl)salicylaldehyde are used as key intermediates in the synthesis of various pharmaceutical compounds. Their unique chemical properties make them valuable building blocks for the development of new drugs with improved pharmacokinetic and pharmacodynamic profiles.
Used in Agrochemical Industry:
These compounds can also be used as intermediates in the synthesis of agrochemicals, such as pesticides and herbicides. The trifluoromethyl group can enhance the biological activity and selectivity of these agrochemicals, leading to more effective and environmentally friendly products.
Used in Flavone Derivatives Synthesis:
Specifically, 2-Hydroxy-4-(trifluoromethyl)benzaldehyde (CAS# 58914-34-4) is used as a reactant in the preparation of flavone derivatives, which have potential applications in the treatment and prophylaxis of hepatitis B virus disease. The trifluoromethyl group in 2-Formyl-5-(trifluoromethyl)phenol, 4-Formyl-3-hydroxybenzotrifluoride, 4-(Trifluoromethyl)salicylaldehyde may contribute to the improved potency and selectivity of the resulting flavone derivatives.

Upstream product

• 108-48-5 2,6-dimethylpyridine 
• 402-45-9 4-hydroxybenzotrifluoride 
• 1609405-64-2 2-methoxy-4-(trifluoromethyl)-1-vinylbenzene 
• 68-12-2 N,N-dimethyl-formamide 
• 100-97-0 hexamethylenetetramine 
• 98-17-9 3-Trifluoromethylphenol 
• 89763-93-9 2-Fluoro-4-(trifluoromethyl)benzaldehyde 
• 50-00-0 formaldehyd 
• 328-90-5 4-trifluoromethylsalicylic acid 
• 1352748-32-3 2-ethoxymethoxy-4-(trifluoromethyl)benzaldehyde 
• 1352748-31-2 1-ethoxymethoxy-3-(trifluoromethyl)benzene 
• 132927-09-4 2-methoxy-4-(trifluoromethyl)benzaldehyde 
• 349-66-6 2-(hydroxymethyl)-5-(trifluoromethyl)phenol 
• 896732-43-7 2-(3-(trifluoromethyl)phenoxy)tetrahydro-2H-pyran 

Downstream Products

• 132927-09-4 2-methoxy-4-(trifluoromethyl)benzaldehyde 
• 1191271-41-6 2-(2-phenyl-allyloxy)-4-trifluoromethyl-benzaldehyde 
• 1191271-14-3 2-allyloxy-4-trifluoromethyl-benzaldehyde 
• 1510865-19-6 2,3-diphenyl-8-(trifluoromethyl)benzo[b]oxepine 
• 334015-45-1 2-(methoxymethoxy)-4-(trifluoromethyl)benzaldehyde 

Relevant academic research and scientific papers

TRANSCRIPTION FACTOR BRN2 INHIBITORY COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE

The invention provides a variety of compounds having the structure of Formula I and uses of such compounds for treatment of various indications, including cancer as well as methods of treatment involving such compounds are also provided. The uses of the compounds may specifically include: bladder cancer, cholangiocarcinoma; colorectal cancer; diffuse large B-cell lymphoma (DLBC); liver cancer; ovarian cancer; thymoma; thyroid cancer; clear cell renal cell carcinoma (CCRCC); chromophobe renal cell carcinoma (ChRCC); prostate cancer; breast cancer; uterine cancer; pancreatic cancer; cervical cancer; uveal melanoma; acute myeloid leukemia (AML); head and neck cancer; small cell lung cancer (SCLC); lung adenocarcinoma sarcoma; mesothelioma; adenoid cystic carcinoma (ACC), sarcoma; testicular germ cell cancer; uterine cancer; pheochromocytoma and paraganglioma (PCPG); melanoma; glioma; glioblastoma multiforme; T-cell Acute Lymphoblastic Leukemia; T-cell Lympohoma, medulloblastoma; and neuroblastoma.

Sequential Energy Transfer Catalysis: A Cascade Synthesis of Angularly-Fused Dihydrocoumarins

An operationally simple one-pot protocol has been developed to enable the conversion of diversely substituted cinnamic acid derivatives into angularly-fused dihydrocoumarins (up to 94%). Inspired by coumarin biosynthesis, this reaction cascade harnesses photochemical E → Z alkene isomerization enabled by energy transfer catalysis using inexpensive thioxanthen-9-one (TX) under irradiation at 402 nm. Subsequent lactonization generates the heterocyclic core prior to a second photosensitization event to induce a [2 + 2] cycloaddition, again mediated by TX. The tetracyclic products are generated efficiently, and proof of the structure was established by X-ray crystallography. Mechanistic investigations, including structural probes and NMR reaction monitoring, support the postulated order of events. The study underscores the synthetic value of inexpensive small-molecule organic photocatalysts in the generation of structural complexity via sequential ?€-bond activation.

NOVEL SUBSTITUTED PYRIDO-PIPERAZINONE DERIVATIVES AS GAMMA SECRETASE MODULATORS

The present invention is concerned with novel substituted pyrido-piperazinone derivatives of Formula (I) wherein R1, R2, R3, R4, R5, L, Z and X have the meaning defined in the claims. The compounds according to the present invention are useful as gamma secretase modulators. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.

MAGL INHIBITORS

Provided herein are piperazine carbamates and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of MAGL. Furthermore, the subject compounds and compositions are useful for the treatment of pain.

MAGL INHIBITORS

Provided herein are spirocyclic and fused bicyclic carbamates and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of MAGL. Furthermore, the subject compounds and compositions are useful for the treatment of pain.

SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME

Provided herein are spirocycle compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of MAGL and/or ABHD6. Furthermore, the subject compounds and compositions are useful for the treatment of pain.

PYRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME

Provided herein are pyrazole compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of MAGL and/or ABHD6. Furthermore, the subject compounds and compositions are useful for the treatment of, for example, pain.

Structure-activity relationship study of E6 as a novel necroptosis inducer

Necroptosis inducers represent a promising potential treatment for drug-resistant cancer. We herein describe the structure modification of E6, which was identified recently as a potent and selective necroptosis inducer. The studies described herein demonstrate for the first time that functionalized biphenyl derivatives possess necroptosis inducer activity. Furthermore, these studies have led to the identification of two promising compounds (5h and 5j) that can be used for further optimization studies as well as mechanism of action investigations.

Straightforward assembly of benzoxepines by means of a rhodium(III)- catalyzed C-H functionalization of o-vinylphenols

Readily available o-vinylphenols undergo a formal (5 + 2) cycloaddition to alkynes when treated with catalytic amounts of [Cp*RhCl2] 2 and Cu(OAc)2. The reaction, which involves the cleavage of the terminal C-H bond of the alkenyl moiety, generates highly valuable benzoxepine skeletons in a practical, versatile, and atom-economical manner. Using carbon monoxide instead of an alkyne as reaction partner leads to coumarin products which formally result from a (5 + 1) cycloaddition.

NOVEL SUBSTITUTED PYRIDO-PIPERAZINONE DERIVATIVES AS GAMMA SECRETASE MODULATORS

The present invention is concerned with novel substituted pyrido-piperazinone derivatives of Formula (I) wherein R1, R2, R3, R4, R5, L, Z and X have the meaning defined in the claims. The compounds according to the present invention are useful as gamma secretase modulators. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.